Renowned oncologist questions Joe Biden’s prostate cancer diagnosis timeline – and when treatments possibly started: ‘Doesn’t make any sense’

A leading oncologist questioned the timeline of former President Biden’s prostate cancer diagnosis, particularly the claim by his doctors that his form of the disease was “hormone sensitive,” which they said allows for more effective treatment.

Speaking on SiriusXM’s “The Megyn Kelly Show,” urology and prostate physician, Dr. David B. Samadi questioned how Biden’s doctors could know this unless the 82-year-old was already undergoing cancer treatment.

“A week ago, they had the prostate nodule. Within a week they did the biopsy and got the disease, so very quickly – based on the story they’re telling – they’ve been able to do the staging part to find out if the cancer has spread to the bone or not,” he said.

“But you have to give the injections and see if the patient responds. We don’t know what his PSA is,” he said, referring to the score for the Prostate-Specific Antigen test — a critical diagnostic for prostate cancer patients.

---

Follow the latest on Joe Biden’s prostate cancer diagnosis:

• Biden cancer diagnosis spurs free prostate screenings in NYC — 8 tips for first-timers
• Biden last underwent common prostate cancer screening in 2014, rep reveals
• Trump accuses Biden allies of ‘not telling the facts’ after cancer diagnosis: ‘Dangerous for our country’
• Renowned oncologist questions Joe Biden’s prostate cancer diagnosis timeline – and when treatments possibly started: ‘Doesn’t make any sense’

---

“If the PSA starts to go down, that’s when you know he’s hormone sensitive. I don’t know how they’d be able to give all of this information from diagnosis to treatment to all of that within one week. The story doesn’t make any sense.”

Another urologic oncologist told The Post that “98-99% if not more” of prostate cancers are sensitive to hormone therapy, “because testosterone is the fuel by which prostate cancer grows.”

“For a patient who’s newly diagnosed with prostate cancer, if we put them on one of the hormone-suppressing medications, we expect their PSA to decline,” said Manish Vira, Chief of Urology at Northwell Health Cancer Institute.

“We expect the cancer to shrink, because virtually all prostate cancers are sensitive to testosterone.”